Literature DB >> 29777528

State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.

Venkata Yellepeddi1,2, Joseph Rower1, Xiaoxi Liu1, Shaun Kumar1, Jahidur Rashid1, Catherine M T Sherwin3,4.   

Abstract

Physiologically based pharmacokinetic modeling and simulation is an important tool for predicting the pharmacokinetics, pharmacodynamics, and safety of drugs in pediatrics. Physiologically based pharmacokinetic modeling is applied in pediatric drug development for first-time-in-pediatric dose selection, simulation-based trial design, correlation with target organ toxicities, risk assessment by investigating possible drug-drug interactions, real-time assessment of pharmacokinetic-safety relationships, and assessment of non-systemic biodistribution targets. This review summarizes the details of a physiologically based pharmacokinetic modeling approach in pediatric drug research, emphasizing reports on pediatric physiologically based pharmacokinetic models of individual drugs. We also compare and contrast the strategies employed by various researchers in pediatric physiologically based pharmacokinetic modeling and provide a comprehensive overview of physiologically based pharmacokinetic modeling strategies and approaches in pediatrics. We discuss the impact of physiologically based pharmacokinetic models on regulatory reviews and product labels in the field of pediatric pharmacotherapy. Additionally, we examine in detail the current limitations and future directions of physiologically based pharmacokinetic modeling in pediatrics with regard to the ability to predict plasma concentrations and pharmacokinetic parameters. Despite the skepticism and concern in the pediatric community about the reliability of physiologically based pharmacokinetic models, there is substantial evidence that pediatric physiologically based pharmacokinetic models have been used successfully to predict differences in pharmacokinetics between adults and children for several drugs. It is obvious that the use of physiologically based pharmacokinetic modeling to support various stages of pediatric drug development is highly attractive and will rapidly increase, provided the robustness and reliability of these techniques are well established.

Entities:  

Mesh:

Year:  2019        PMID: 29777528     DOI: 10.1007/s40262-018-0677-y

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  74 in total

1.  Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation.

Authors:  P Robinan Gentry; Tammie R Covington; Harvey J Clewell
Journal:  Regul Toxicol Pharmacol       Date:  2003-08       Impact factor: 3.271

2.  Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification.

Authors:  Zofia Tylutki; Aleksander Mendyk; Sebastian Polak
Journal:  J Pharm Sci       Date:  2017-11-23       Impact factor: 3.534

3.  Maturation and growth of renal function: dosing renally cleared drugs in children.

Authors:  W L Hayton
Journal:  AAPS PharmSci       Date:  2000

4.  Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.

Authors:  Trevor N Johnson; Diansong Zhou; Khanh H Bui
Journal:  Biopharm Drug Dispos       Date:  2014-08-06       Impact factor: 1.627

Review 5.  Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.

Authors:  A A Vinks; C Emoto; T Fukuda
Journal:  Clin Pharmacol Ther       Date:  2015-07-20       Impact factor: 6.875

Review 6.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

7.  A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.

Authors:  A R Maharaj; J S Barrett; A N Edginton
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

Review 8.  Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.

Authors:  Nathalie Rioux; Nigel J Waters
Journal:  Drug Metab Dispos       Date:  2016-03-02       Impact factor: 3.922

Review 9.  Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.

Authors:  Feras Khalil; Stephanie Läer
Journal:  J Biomed Biotechnol       Date:  2011-06-01

10.  Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children.

Authors:  X-L Jiang; P Zhao; J S Barrett; L J Lesko; S Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-10-16
View more
  21 in total

Review 1.  The Pediatric Cell Atlas: Defining the Growth Phase of Human Development at Single-Cell Resolution.

Authors:  Deanne M Taylor; Bruce J Aronow; Kai Tan; Kathrin Bernt; Nathan Salomonis; Casey S Greene; Alina Frolova; Sarah E Henrickson; Andrew Wells; Liming Pei; Jyoti K Jaiswal; Jeffrey Whitsett; Kathryn E Hamilton; Sonya A MacParland; Judith Kelsen; Robert O Heuckeroth; S Steven Potter; Laura A Vella; Natalie A Terry; Louis R Ghanem; Benjamin C Kennedy; Ingo Helbig; Kathleen E Sullivan; Leslie Castelo-Soccio; Arnold Kreigstein; Florian Herse; Martijn C Nawijn; Gerard H Koppelman; Melissa Haendel; Nomi L Harris; Jo Lynne Rokita; Yuanchao Zhang; Aviv Regev; Orit Rozenblatt-Rosen; Jennifer E Rood; Timothy L Tickle; Roser Vento-Tormo; Saif Alimohamed; Monkol Lek; Jessica C Mar; Kathleen M Loomes; David M Barrett; Prech Uapinyoying; Alan H Beggs; Pankaj B Agrawal; Yi-Wen Chen; Amanda B Muir; Lana X Garmire; Scott B Snapper; Javad Nazarian; Steven H Seeholzer; Hossein Fazelinia; Larry N Singh; Robert B Faryabi; Pichai Raman; Noor Dawany; Hongbo Michael Xie; Batsal Devkota; Sharon J Diskin; Stewart A Anderson; Eric F Rappaport; William Peranteau; Kathryn A Wikenheiser-Brokamp; Sarah Teichmann; Douglas Wallace; Tao Peng; Yang-Yang Ding; Man S Kim; Yi Xing; Sek Won Kong; Carsten G Bönnemann; Kenneth D Mandl; Peter S White
Journal:  Dev Cell       Date:  2019-03-28       Impact factor: 12.270

2.  A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model.

Authors:  Alexander P Klapproth; Maxim Shevtsov; Stefan Stangl; Wei Bo Li; Gabriele Multhoff
Journal:  Int J Nanomedicine       Date:  2020-06-30

3.  Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.

Authors:  Chang-Keun Cho; Pureum Kang; Hye-Jung Park; Eunvin Ko; Chou Yen Mu; Yun Jeong Lee; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-05-31       Impact factor: 4.946

4.  Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.

Authors:  Choong-Min Lee; Pureum Kang; Chang-Keun Cho; Hye-Jung Park; Yun Jeong Lee; Jung-Woo Bae; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-06-28       Impact factor: 4.946

Review 5.  Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy.

Authors:  Katherine L Gill; Hannah M Jones
Journal:  AAPS J       Date:  2022-06-01       Impact factor: 3.603

Review 6.  Progress in Isoindolone Alkaloid Derivatives from Marine Microorganism: Pharmacology, Preparation, and Mechanism.

Authors:  Sijin Hang; Hui Chen; Wenhui Wu; Shiyi Wang; Yiwen Fang; Ruilong Sheng; Qidong Tu; Ruihua Guo
Journal:  Mar Drugs       Date:  2022-06-20       Impact factor: 6.085

7.  A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate.

Authors:  Qier Wu; Sheila Annie Peters
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-02-26

8.  Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients.

Authors:  Paul R V Malik; Andrea N Edginton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-19

9.  Neural-ODE for pharmacokinetics modeling and its advantage to alternative machine learning models in predicting new dosing regimens.

Authors:  James Lu; Kaiwen Deng; Xinyuan Zhang; Gengbo Liu; Yuanfang Guan
Journal:  iScience       Date:  2021-06-30

Review 10.  The Challenges of Pediatric Drug Development.

Authors:  Klaus Rose
Journal:  Curr Ther Res Clin Exp       Date:  2019-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.